Malignant Breast Neoplasm

MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the resistant clone (TKi-R). A novel mTOR inhibitor … (full text at CIViC)

PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC

In this retrospective analysis of 211 breast cancer tissues, MYD88 overexpression was correlated with poor survival. In-vitro experiments showed a decrease in sensitivity towards paclitaxel in cell-l… (full text at CIViC)

PMID 26596839 · Xiang et al., 2016 · Open in CIViC

In patients with breast cancer, those with amplification of NCOA3 had shorter disease-specific survival.

PMID 23322234 · Burandt et al., 2013 · Open in CIViC

High expression determined by immunohistochemistry of NCOA3 was found in 571 out of 1,836 breast cancer samples. Those with high expression had worse overall and disease-specific survival.

PMID 23322234 · Burandt et al., 2013 · Open in CIViC

23 patients were treated with temsirolimus containing regimens. 1 patient with a complete response >3 years had a K159fs*16 mutation in NF2. 2 patients were tested for NF2 mutations.

PMID 25878190 · Moulder et al., 2015 · Open in CIViC

In the multicenter open-label single-arm non-interventional STEPAUT study of postmenopausal women with HR+, HER2− advanced breast cancer progressing or recurring on/after prior NSAIs (n = 236), the HR… (full text at CIViC)

PMID 32062536 · Steger et al., 2020 · Open in CIViC

In a clinical study of 49 patients, 10 patients with Breast Cancer (BC) and wild-type NRAS gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. PFS of 6.7 weeks (95% CI… (full text at CIViC)

PMID 33090333 · Fisher et al., 2020 · Open in CIViC

Reactivation of EGFR, HER2 and HER3 occurred within 24 hours of lapatinib treatment in breast cancer cell lines, This was associated with increased expression of NRG1 in cells treated with lapatinib.

PMID 25691057 · Leung et al., 2015 · Open in CIViC

Study explored the known PALB2 variant c.1592delT (p.L531C) in the context of breast cancer. The study found that among an augmented cohort of breast cancer patients with the variant, there was a haza… (full text at CIViC)

PMID 18628482 · Erkko et al., 2008 · Open in CIViC

Multi-gene cancer predisposition panel testing of a 44-year-old patient diagnosed with rectal cancer revealed a pathogenic PALB2 c.2509G>T variant. This patient had a family history of breast cancer a… (full text at CIViC)

PMID 26270727 · Desmond et al., 2015 · Open in CIViC

In a phase2 trial, patients with breast cancer harboring mutations in homologous recombination pathway genes other than BRCA1/2 were treated with olaparib. Among 6 patients with breast cancer harbori… (full text at CIViC)

Open in CIViC

Multi-gene cancer predisposition panel testing of a 51 year old patient diagnosed with breast cancer revealed a pathogenic PALB2 c.1240C>T, p.R414X variant. This patient had a family history of cancer… (full text at CIViC)

PMID 26270727 · Desmond et al., 2015 · Open in CIViC

Researchers compared biomarkers in breast cancer stem cell (BCSC) enriched and mature cancer cell populations from human breast cancer cell lines. Overexpression of PARP1 was found in BCSC enriched p… (full text at CIViC)

PMID 25144364 · Gilabert et al., 2014 · Open in CIViC

In patients with breast cancer, those with low expression of PgR had worse disease-free survival than those with high expression.

PMID 21422407 · Bartlett et al., 2011 · Open in CIViC

In patients with breast cancer, those with expression of PgR (determined by immunohistochemical staining) had better relapse-free survival than those without expression.

PMID 16497822 · Dowsett et al., 2006 · Open in CIViC

In patients with ER-Positive breast cancer, expression of PgR does not effect the outcome of treatment with tamoxifen.

In a preclinical study, efficacy of NVP-BEZ235 (dactolisib) and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with retrovirally induced PI… (full text at CIViC)

PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC

In a preclinical study, efficacy of NVP-BEZ235 (dactolisib), lapatinib, and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with retrovirall… (full text at CIViC)

PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC

In this randomized, phase III trial, 572 patients with HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously underwent randomization, including 341 patients w… (full text at CIViC)

PMID 31091374 · André et al., 2019 · Open in CIViC

This preclinical study tested the efficacy on several HER2 amplified breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of … (full text at CIViC)

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

The phase III INAVO120 trial (NCT04191499) in 325 patients with endocrine-resistant, PIK3CA-mutated HR⁺/HER2⁻ locally advanced or metastatic breast cancer evaluated inavolisib plus palbociclib and ful… (full text at CIViC)

PMID 40845250 · Wedam et al., 2025 · Open in CIViC

In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or… (full text at CIViC)

PMID 31091374 · André et al., 2019 · Open in CIViC

Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.

PMID 21558396 · Tanaka et al., 2011 · Open in CIViC

The phase III INAVO120 trial (NCT04191499) in 325 patients with endocrine-resistant, PIK3CA-mutated HR⁺/HER2⁻ locally advanced or metastatic breast cancer evaluated inavolisib plus palbociclib and ful… (full text at CIViC)

PMID 40845250 · Wedam et al., 2025 · Open in CIViC

This study of 140 patients with stage II-III breast cancer assessed the response of patients with PIK3CA mutations to 6 months of preoperative chemotherapy. Exons 1, 9, and 20 of PIK3CA were screened… (full text at CIViC)

PMID 18371219 · Liedtke et al., 2008 · Open in CIViC

In HER2-positive metastic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation was associated with an increased risk of progression (HR:2.50, 95% CI:1.35-4.… (full text at CIViC)

PMID 21594665 · Razis et al., 2011 · Open in CIViC

PIK3CA E545K mutation increased sensitivity to AKT inhibitor MK-2206 and PI3K inhibitor GDC-0941 in a breast cancer cell line model.

PMID 23888070 · Beaver et al., 2013 · Open in CIViC

This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA E545K to NVP-BEZ235 (dactolisib; a dua… (full text at CIViC)

PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC